Drug Target Review – Publications

Issue #3 2020

The next issue of Drug Target Review goes to press on  03 September 2020 and will feature:

• In-Depth Focuses on: Assays, Antibodies, NGS and Targets
• A focus on the latest advances in Neuroscience and Synthetic Biology
• The latest trends in Flow Cytometry
• And much more…

To receive our latest journal, you can secure your free print and/or digital copy here.

Latest issue

Issue #2 2020

Drug Target Review – Issue 2 2020

In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute…

By Drug Target Review

Issue #2 2020

Screening In-Depth Focus 2020

Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics…

By Drug Target Review

Issue #2 2020

Immuno-oncology In-Depth Focus 2020

This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how…

By Drug Target Review

Issue #2 2020

Imaging In-Depth Focus 2020

The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell…

By Drug Target Review

Issue #2 2020

Stem Cells In-Deth Focus 2020

The stem cells in-depth focus includes articles on using computational approaches to expand the applications of stem cell therapies and…

By Drug Target Review

Issue #2 2020

Expert view: Critical consumables: meeting the need for a steady…

In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust…

By Merck

Issue #2 2020

Application note: Screening for optimal association and dissociation rates of…

Potential drugs not only need to bind to their targets, they also need to remain bound for a specific amount…

By BMG Labtech GmbH

Issue #2 2020

Application note: Improvement of bovine parainfluenza 3 virus production yields…

Parainfluenza 3 (PI3V) is a virus that causes respiratory diseases in calves, from the common cold to advanced pneumonia.

By Corning Life Sciences

Issue #2 2020

Expert view: Finding a translatable disease model suitable for drug…

Effective drug discovery and development greatly relies on the availability of predictive pre-clinical models.

By Ncardia

Issue #2 2020

Expert view: CRISPR screening: a powerful approach to drug discovery…

CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to…

By Horizon Discovery

Issue #2 2020

Application note: Monitoring of SMALP-nanodisc formation by microfluidic diffusional sizing

Styrene–maleic acid (SMA) copolymers have become popular tools used in membraneprotein research as they can extract both lipids and membrane…

Issue #2 2020

Application note: High-throughput sialylation screening in combination with titer monitoring…

Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product…

By ForteBio

Issue #2 2020

Application note: CRISPR-Cas9 screening for target identification

The identification and validation of novel drug targets is a challenging process for drug discovery programmes.

By Horizon Discovery

Issue #2 2020

Expert view: High-throughput analytics for smarter cell-line development

Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing…

By ForteBio

Issue #2 2020

Expert view: From 3D high throughput to simple automated imaging:…

Our Ability to image cells has come a long way since the pioneering days of Galileo Galilei and Antonie van…

By Molecular Devices

Issue #2 2020

Expert view: Delivering better therapeutics: fully characterising and recovering T…

T cell-based therapies have shown promise as new treatment options for various cancers.

By Berkeley Lights

Issue #2 2020

Expert view: GenScript’s unique four-tier platform for successful synthesis of…

Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.

By GenScript

Issue #2 2020

Neoantigens: presenting new vaccine opportunities in immuno-oncology

Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response.…

By Nikki Withers (Drug Target Review)

Issue #2 2020

Triplet immuno-oncology drug combinations – the future of treating multiple…

The oncology market is saturated with new drugs that target the immune system, however, these only target part of the…

By Miguel Ferreira

Issue #2 2020

Current state of NAFLD treatments and the promise of in…

The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This…

By Aslihan Gokaltun (Harvard Medical School and Shriners Hospitals for Children), Beyza Bulutoglu (Harvard Medical School and Shriners Hospitals for Children), Camilo Rey-Bedón (Harvard Medical School and Shriners Hospitals for Children), Martin L Yarmush (Harvard Medical School and Shriners Hospitals for Children), Osman Berk Usta (Harvard Medical School and Shriners Hospitals for Children), Peony Banik (Harvard Medical School and Shriners Hospitals for Children)

Issue #2 2020

If Columbus had a map… guiding the discovery of new…

Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and…

By Horst Flotow (GDBspace), Jingwen Shi (GDBspace), Sacha Javor (GDBspace)

Issue #2 2020

High-throughput screening as a method for discovering new drugs

High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes –…

By Mathew Lloyd (University of Bath)

Issue #2 2020

The Crick HTS facility – facilitating research through large-scale screening

The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research…

By Michael Howell (Francis Crick Institute)

Issue #2 2020

Delivering a therapy to kerb COVID-19

Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.

By Sheraz Gul (Fraunhofer Institute)

Issue #2 2020

Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy

Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and…

By Shalom Gurjar (OXGENE)

Issue #2 2020

Data, data and still more data: the challenges of imaging…

The latest generation of three-dimensional (3D) cell models offer new and exciting possibilities for pharmaceutical research. However, deciding how to…

By Jeremy Simpson (University College Dublin), Margaritha Mysior (University College Dublin)

Issue #2 2020

Seeing the light – visualising protein translation in real time

Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who…

By Nikki Withers (Drug Target Review)

Issue #2 2020

Using genetics to identify drug targets for fibrotic lung diseases

Researchers recently conducted a genome-wide association study (GWAS) to identify factors that increase susceptibility to the incurable lung condition idiopathic…

By Richard Allen (University of Leicester)

Issue #2 2020

Using big data approaches to develop cell therapies

An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current…

By Dr Owen Rackham (Duke-NUS Medical School)

Issue #2 2020

Application of organoid technology for retinal disease modelling and drug…

The loss of retinal light-sensing photoreceptor cells is a leading cause of blindness and the number of individuals affected by…

By Valeria Chichagova (Newcastle University and Newcells Biotech)

Past Issues

Issue #1 2020

Drug Target Review – Issue 1 2020

Issue #4 2019

Drug Target Review – Issue 4 2019

Issue #3 2019

Drug Target Review – Issue 3 2019

Issue #2 2019

Drug Target Review – Issue 2 2019

Issue #1 2019

Drug Target Review – Issue 1 2019

Issue #4 2018

Drug Target Review – Issue 4 2018

Issue #3 2018

Drug Target Review – Issue 3 2018

Issue #2 2018

Drug Target Review – Issue #2 2018

Issue #1 2018

Drug Target Review – Issue #1 2018

Issue #4 2017

Drug Target Review – Issue #4 2017

Issue #3 2017

Drug Target Review – Issue #3 2017

Issue #2 2017

Drug Target Review – Issue #2 2017

Issue #1 2017

Drug Target Review – Issue #1 2017

Issue #4 2016

Drug Target Review – Issue #4 2016

Issue #3 2016

Drug Target Review – Issue #3 2016

Supplements & Special Editions

Issue #1 2020

Lab Automation In-Depth Focus 2020

Issue #1 2020

Informatics In-Depth Focus 2020

Issue #1 2020

Antibodies In-Depth Focus 2020

Issue #1 2020

Assays In-Depth Focus 2020

Issue #4 2019

Hit-To-Lead In-Depth Focus 2019

Issue #4 2019

Targets In-Depth Focus 2019

Issue #4 2019

Screening In-Depth Focus 2019

Issue #3 2019

Upstream Bioprocessing In-Depth Focus 2019

Issue #3 2019

Antibodies In-Depth Focus 2019

Issue #3 2019

Genomics In-Depth Focus 2019

Issue #2 2019

Screening In-Depth Focus 2019

Issue #2 2019

Imaging In-Depth Focus 2019

Issue #2 2019

Stem Cell In-Depth Focus 2019

Issue #1 2019

Lab Automation In-Depth Focus 2019

Issue #1 2019

Informatics In-Depth Focus 2019